Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment
0301 basic medicine
Cell Death
Dose-Response Relationship, Drug
Cell Survival
Pyridines
Imidazoles
Mice, Nude
HCT116 Cells
Heterocyclic Compounds, 4 or More Rings
Xenograft Model Antitumor Assays
3. Good health
Killer Cells, Natural
TNF-Related Apoptosis-Inducing Ligand
Mice
03 medical and health sciences
Pyrimidines
Animals
Humans
Female
Neoplasm Metastasis
Colorectal Neoplasms
Cell Proliferation
Signal Transduction
DOI:
10.1172/jci96711
Publication Date:
2018-03-20T20:43:16Z
AUTHORS (17)
ABSTRACT
ONC201 is a first-in-class, orally active antitumor agent that upregulates cytotoxic TRAIL pathway signaling in cancer cells. has demonstrated safety and preliminary efficacy first-in-human trial which patients were dosed every 3 weeks. We hypothesized dose intensification of may impact efficacy. discovered exerts dose- schedule-dependent effects on tumor progression cell death vivo. With intensification, we note potent anti-metastasis effect inhibition migration invasion. Our preclinical results prompted change dosing all open clinical trials. observed accumulation activated NK+ CD3+ cells within ONC201-treated tumors NK depletion inhibits vivo, including against TRAIL/ONC201-resistant Bax–/– tumors. Immunocompetent NCR1-GFP mice, express GFP, GFP+ infiltration syngeneic MC38 colorectal Activation primary human increased degranulation occurred response to ONC201. Coculture experiments identified role for NK-mediated cytotoxicity. Preclinical indicate the potential utility plus anti–PD-1 therapy. an increase TRAIL-secreting peripheral blood after treatment. The offer what believe be unique immune stimulation
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (34)
CITATIONS (62)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....